• Je něco špatně v tomto záznamu ?

Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial

J. Sperl, G. Horvath, W. Halota, JA. Ruiz-Tapiador, A. Streinu-Cercel, L. Jancoriene, K. Werling, H. Kileng, S. Koklu, J. Gerstoft, P. Urbanek, R. Flisiak, R. Leiva, E. Kazenaite, R. Prinzing, S. Patel, J. Qiu, E. Asante-Appiah, J. Wahl, BY....

. 2016 ; 65 (6) : 1112-1119. [pub] 20160816

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025328

BACKGROUND & AIMS: Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV) infection; however, head-to-head comparisons are limited. The C-EDGE Head-2-Head Study compared the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) with sofosbuvir plus pegylated interferon/ribavirin (SOF/PR) in patients with HCV infection. METHODS: This was a randomized, open-label, phase III trial. Two hundred fifty-seven patients with HCV genotype (GT)1 or 4 infection and baseline viral load >10,000IU/ml were randomized to receive 12weeks of EBR/GZR 50mg/100mg once daily (n=129) or sofosbuvir (400mg once daily) plus PR (n=128). Primary efficacy objective was sustained virologic response 12weeks after the end of therapy (SVR12, HCV RNA <15IU/ml). The primary safety objective was the proportion of patients experiencing a tier 1 safety event. RESULTS: The majority of patients were non-cirrhotic (83.1%), treatment-naïve (74.9%) and had HCV GT1b infection (82.0%). SVR12 rates were 99.2% (128/129) and 90.5% (114/126) in the EBR/GZR and SOF/PR groups, respectively. The estimated adjusted difference in SVR12 was 8.8% (95% confidence interval [CI], 3.6-15.3%). Because the lower bound of the 1-sided 1-sample exact test was greater than -10% and greater than zero, both non-inferiority and superiority of EBR/GZR vs. SOF/PR were established. The frequency of tier 1 safety events was lower among patients receiving EBR/GZR than SOF/PR (0.8% vs. 27.8%, between group difference, 27.0% [95% CI, -35.5% to -19.6%; p<0.001]). CONCLUSIONS: EBR/GZR has a superior efficacy and safety profile in patients with HCV GT1 or 4 infection compared with SOF/PR. LAY SUMMARY: The combination of elbasvir/grazoprevir for 12weeks was highly effective in treating patients with chronic hepatitis C, genotypes 1 or 4 infection. This regimen was more effective than sofosbuvir/pegylated interferon/ribavirin for 12weeks, and was notably superior in patients regarded as difficult to treat, including those with previous treatment failure, cirrhosis, or a high baseline viral load. The combination of elbasvir/grazoprevir also demonstrated a superior safety and tolerability profile based on fewer serious adverse events, no serious drug-related adverse events, and no treatment discontinuations. CLINICAL TRIAL REGISTRATION: Clinical trials.gov Identifier: NCT02358044.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025328
003      
CZ-PrNML
005      
20180716123533.0
007      
ta
008      
180709s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jhep.2016.07.050 $2 doi
035    __
$a (PubMed)27542322
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Sperl, Jan $u Institut Klinické a Experimentální Medicíny (IKEM), Prague, Czech Republic. Electronic address: jase@medicon.cz.
245    10
$a Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial / $c J. Sperl, G. Horvath, W. Halota, JA. Ruiz-Tapiador, A. Streinu-Cercel, L. Jancoriene, K. Werling, H. Kileng, S. Koklu, J. Gerstoft, P. Urbanek, R. Flisiak, R. Leiva, E. Kazenaite, R. Prinzing, S. Patel, J. Qiu, E. Asante-Appiah, J. Wahl, BY. Nguyen, E. Barr, HL. Platt,
520    9_
$a BACKGROUND & AIMS: Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV) infection; however, head-to-head comparisons are limited. The C-EDGE Head-2-Head Study compared the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) with sofosbuvir plus pegylated interferon/ribavirin (SOF/PR) in patients with HCV infection. METHODS: This was a randomized, open-label, phase III trial. Two hundred fifty-seven patients with HCV genotype (GT)1 or 4 infection and baseline viral load >10,000IU/ml were randomized to receive 12weeks of EBR/GZR 50mg/100mg once daily (n=129) or sofosbuvir (400mg once daily) plus PR (n=128). Primary efficacy objective was sustained virologic response 12weeks after the end of therapy (SVR12, HCV RNA <15IU/ml). The primary safety objective was the proportion of patients experiencing a tier 1 safety event. RESULTS: The majority of patients were non-cirrhotic (83.1%), treatment-naïve (74.9%) and had HCV GT1b infection (82.0%). SVR12 rates were 99.2% (128/129) and 90.5% (114/126) in the EBR/GZR and SOF/PR groups, respectively. The estimated adjusted difference in SVR12 was 8.8% (95% confidence interval [CI], 3.6-15.3%). Because the lower bound of the 1-sided 1-sample exact test was greater than -10% and greater than zero, both non-inferiority and superiority of EBR/GZR vs. SOF/PR were established. The frequency of tier 1 safety events was lower among patients receiving EBR/GZR than SOF/PR (0.8% vs. 27.8%, between group difference, 27.0% [95% CI, -35.5% to -19.6%; p<0.001]). CONCLUSIONS: EBR/GZR has a superior efficacy and safety profile in patients with HCV GT1 or 4 infection compared with SOF/PR. LAY SUMMARY: The combination of elbasvir/grazoprevir for 12weeks was highly effective in treating patients with chronic hepatitis C, genotypes 1 or 4 infection. This regimen was more effective than sofosbuvir/pegylated interferon/ribavirin for 12weeks, and was notably superior in patients regarded as difficult to treat, including those with previous treatment failure, cirrhosis, or a high baseline viral load. The combination of elbasvir/grazoprevir also demonstrated a superior safety and tolerability profile based on fewer serious adverse events, no serious drug-related adverse events, and no treatment discontinuations. CLINICAL TRIAL REGISTRATION: Clinical trials.gov Identifier: NCT02358044.
650    _2
$a antivirové látky $7 D000998
650    _2
$a benzofurany $7 D001572
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a genotyp $7 D005838
650    _2
$a Hepacivirus $7 D016174
650    12
$a chronická hepatitida C $7 D019698
650    _2
$a lidé $7 D006801
650    _2
$a imidazoly $7 D007093
650    _2
$a interferony $7 D007372
650    _2
$a chinoxaliny $7 D011810
650    _2
$a RNA virová $7 D012367
650    _2
$a ribavirin $7 D012254
650    _2
$a sofosbuvir $7 D000069474
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Horvath, Gabor $u Budai Hepatólogiai Centrum, Budapest, Hungary.
700    1_
$a Halota, Waldemar $u Department of Infectious Diseases and Hepatology, Faculty of Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland.
700    1_
$a Ruiz-Tapiador, Juan Arenas $u Hospital Universitario Donostia, Gipuzkoa, Spain.
700    1_
$a Streinu-Cercel, Anca $u Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. Matei Balș", Bucharest, Romania.
700    1_
$a Jancoriene, Ligita $u Vilnius University, Department of Infectious and Chest Diseases, Dermatovenerology and Alergology, Vilnius University Hospital Santariškių Klinikos, Vilnius, Lithuania.
700    1_
$a Werling, Klara $u Semmelweis Egyetem, Budapest, Hungary.
700    1_
$a Kileng, Hege $u UNN Universitetssykehuset Nord Norge, Tromsø, Norway.
700    1_
$a Koklu, Seyfettin $u Hacettepe University Medical Faculty, Ankara, Turkey.
700    1_
$a Gerstoft, Jan $u Klinik for Infektionsmedicin, Rigshospitalet, University of Copenhagen, Denmark.
700    1_
$a Urbanek, Petr $u Department of Internal Medicine, 1st Medical Faculty Charles University and Central Military Hospital, Prague, Czech Republic.
700    1_
$a Flisiak, Robert $u Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
700    1_
$a Leiva, Rafael $u Haukeland University Hospital, Bergen, Norway.
700    1_
$a Kazenaite, Edita $u Vilnius University, Faculty of Medicine, Vilnius University Hospital Santariškių Klinikos, Vilnius, Lithuania.
700    1_
$a Prinzing, Renate $u Merck & Co., Inc., Kenilworth, NJ, United States.
700    1_
$a Patel, Sushma $u Merck & Co., Inc., Kenilworth, NJ, United States.
700    1_
$a Qiu, Jingjun $u Merck & Co., Inc., Kenilworth, NJ, United States.
700    1_
$a Asante-Appiah, Ernest $u Merck & Co., Inc., Kenilworth, NJ, United States.
700    1_
$a Wahl, Janice $u Merck & Co., Inc., Kenilworth, NJ, United States.
700    1_
$a Nguyen, Bach-Yen $u Merck & Co., Inc., Kenilworth, NJ, United States.
700    1_
$a Barr, Eliav $u Merck & Co., Inc., Kenilworth, NJ, United States.
700    1_
$a Platt, Heather L $u Merck & Co., Inc., Kenilworth, NJ, United States.
773    0_
$w MED00010017 $t Journal of hepatology $x 1600-0641 $g Roč. 65, č. 6 (2016), s. 1112-1119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27542322 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180716123831 $b ABA008
999    __
$a ok $b bmc $g 1317459 $s 1022249
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 65 $c 6 $d 1112-1119 $e 20160816 $i 1600-0641 $m Journal of hepatology $n J Hepatol $x MED00010017
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace